EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

A Roadmap of CAR-T-Cell Therapy in Glioblastoma: Challenges and Future Perspectives

Megan Montoya iD, Marco Gallus, Su Phyu, Jeffrey Haegelin, John de Groot, Hideho Okada iD

Cells · 23.04.2024 · 13 (9) · 726

DOI: 10.3390/cells13090726 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 23.04.2024. Verfasst von Megan Montoya und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurological Surgery, University of California San Francisco, San Francisco, CA 94143, USA. Hauptthemen laut MEDLINE: Glioblastoma, Immunotherapy, Adoptive, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 200 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, NIH HHS, NIH/NINDS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma (GBM) is the most common primary malignant brain tumor, with a median overall survival of less than 2 years and a nearly 100% mortality rate under standard therapy that consists of surgery followed by combined radiochemotherapy. Therefore, new therapeutic strategies are urgently needed. The success of chimeric antigen receptor (CAR) T cells in hematological cancers has prompted preclinical and clinical investigations into CAR-T-cell treatment for GBM. However, recent trials have not demonstrated any major success. Here, we delineate existing challenges impeding the effectiveness of CAR-T-cell therapy for GBM, encompassing the cold (immunosuppressive) microenvironment, tumor heterogeneity, T-cell exhaustion, local and systemic immunosuppression, and the immune privilege inherent to the central nervous system (CNS) parenchyma. Additionally, we deliberate on the progress made in developing next-generation CAR-T cells and novel innovative approaches, such as low-intensity pulsed focused ultrasound, aimed at surmounting current roadblocks in GBM CAR-T-cell therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaImmunotherapy, AdoptiveReceptors, Chimeric AntigenHumansTumor MicroenvironmentBrain NeoplasmsT-LymphocytesAnimals

Stichwörter der Autor:innen

CAR-T-cell therapyglioblastomatumor immune microenvironment

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Department of Neurological Surgery, University of California San Francisco, San Francisco, CA 94143, USA.
  • Helen Diller Family Comprehensive Cancer Center, San Francisco, CA 94158, USA.
  • Parker Institute for Cancer Immunotherapy, San Francisco, CA 94129, USA.

ORCID-Profile: Megan Montoya, Hideho Okada

Förderung

  • NINDS NIH HHS
  • NIH HHS
  • NIH/NINDS
  • German Research Foundation (DFG)

Zitieren

APA

Montoya, M., Gallus, M., Phyu, S., Haegelin, J., de Groot, J., & Okada, H. (2024). A Roadmap of CAR-T-Cell Therapy in Glioblastoma: Challenges and Future Perspectives. Cells, 13(9), 726. https://doi.org/10.3390/cells13090726

Vancouver

Montoya M, Gallus M, Phyu S, Haegelin J, de Groot J, Okada H. A Roadmap of CAR-T-Cell Therapy in Glioblastoma: Challenges and Future Perspectives. Cells. 2024;13(9):726. doi:10.3390/cells13090726

BibTeX
@article{Montoya2024,
  author = {Montoya, Megan and Gallus, Marco and Phyu, Su and Haegelin, Jeffrey and de Groot, John and Okada, Hideho},
  title = {A Roadmap of CAR-T-Cell Therapy in Glioblastoma: Challenges and Future Perspectives},
  journal = {Cells},
  year = {2024},
  volume = {13},
  number = {9},
  pages = {726},
  doi = {10.3390/cells13090726}
}
Kostenlos starten →